BEIJING, Dec. 17, 2025 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technology and marketing to enhance its business partners' sales growth and commercial value, today announced that it has recently acquired an additional 230 Bitcoin using internal sources of capital, for total purchase price of approximately US $24,610,000. Following the completion of this transaction, the Company's total Bitcoin ho ...

Core Insights - CIMG Inc. has signed a sales contract for computing power equipment valued at approximately USD 106.5 million with a prominent commercial bank in China, marking a significant advancement in its computing power business segment [1][2] Company Overview - CIMG Inc. operates in the digital health industry, focusing on cryptocurrency strategies and leveraging AI and cryptocurrencies to enhance user acquisition and brand management for its clients [3]

Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous partial pressure of oxygen BERKELEY, Calif, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, pr ...

Core Insights - Hims & Hers Health, Inc. (HIMS) operates a technology-driven digital health platform that provides personalized care through software, data, and virtual clinical workflows [1][2] - The company has launched new services, including Labs for biomarker tracking and expanded offerings in menopause and men's health [2][7] - Recent acquisitions, including Livewell and YourBio Health, enhance HIMS' diagnostic capabilities and geographic reach [3][7] Company Developments - Hims & Hers has introduced Labs, allowing customers to monitor biomarkers and receive personalized action plans from doctors [2][7] - The company has expanded into menopause care and launched branded testosterone treatments with at-home testing options [2][7] - The acquisition of Livewell marks HIMS' entry into Canada, while YourBio Health integrates blood-sampling technology into its platform [3][7] Financial Performance - Hims & Hers shares have increased by 56.7% year to date, outperforming the industry growth of 8.1% [6] - The forward 12-month price-to-sales ratio for HIMS is 3.2X, lower than the industry average of 4.9X but higher than its three-year median of 2.6X [9] - The Zacks Consensus Estimate for HIMS' 2025 earnings per share indicates a 77.8% improvement from 2024 [9]

Core Insights - Profusa, Inc. is set to present findings from its pilot clinical study on Lumee technology for tissue oxygen monitoring in peripheral artery disease (PAD) patients at the Leipzig Interventional Course (LINC) 2026 [1][2] - The Lumee technology allows for continuous, real-time measurement of tissue oxygen, intended for both clinical and home use, with positive feedback received from the U.S.-based clinical study [2][3] - Profusa aims to provide personalized biochemical signatures through its long-lasting, injectable biosensors and intelligent data platform, enhancing the reliability of medical data for clinicians [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focusing on the development of tissue-integrated sensors that transmit actionable medical-grade data [3] - The company is led by experienced scientific founders and management, supported by a world-class board of directors [3] - Profusa's mission is to create affordable biosensors that provide continuous monitoring of biochemistry, thereby improving patient care and outcomes [3]

Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany ...

Core Insights - DarioHealth Corp. has launched the Dario Health app enhanced with DarioIQ™, marking a significant milestone in its GenAI roadmap aimed at improving chronic condition management through conversational AI [1][6][7] Group 1: Product Launch and Features - The DarioIQ™ system integrates behavioral insights, real-time biometric interpretation, and personalized guidance, operating alongside Dario's existing mobile application and human coaching framework [2][5] - The initial launch targets hypertension members, allowing Dario to refine the conversational experience before expanding to other chronic conditions such as diabetes and weight management [3][4] Group 2: Strategic Approach - Dario's direct-to-consumer market strategy is designed to validate user interactions and ensure safety and performance within a controlled environment, which will later support B2B partnerships [5][6] - The AI capabilities of DarioIQ™ include three components: Advisor for personalized guidance, Sentinel for timely interventions, and Strategist for actionable insights, all built on Dario's proprietary AI models and 13 billion real-world data points [6][7] Group 3: Company Positioning - DarioHealth positions itself as a leader in digital health, focusing on user-centric solutions that provide continuous and customized care for chronic conditions, disrupting traditional episodic healthcare approaches [8][9] - The company aims to enhance user satisfaction and retention through its innovative platform, which emphasizes sustainable behavior change [9][10]

Core Insights - NeuralCloud is enhancing its global wellness and B2B health practitioner delivery model through high-fidelity cardiac signal processing and digital health integration [1] - The partnership positions MaxYield™ as a central AI engine for next-generation smart rings and consumer cardiac monitoring within the broader INTRINSICA platform [1]

Core Insights - CIMG Inc. has entered into two sales contracts for computing power products, totaling approximately USD 1,779,070, marking a significant step in its strategic expansion into the computing power sector [1][2][3] Group 1: Company Strategy - The expansion into the computing power sector is a strategic initiative launched in Q4 2025, following a partnership with Inspur Electronic Information Industry Co., Ltd. to distribute products through offline channels [2] - CIMG plans to intensify its focus on the computing power sector and accelerate business development in this area to enhance overall competitiveness and resilience [3] Group 2: Sales Contracts - Zhongyan Shangyue Technology Co., Ltd., a subsidiary of CIMG, signed a contract for the sale of 64 high-performance computing servers designed for ultra-high-density computing and AI large model training [7] - Beijing Xinmiao Shidai Technology Co., Ltd., another subsidiary, entered into a contract for the delivery of 145 NVIDIA graphics cards [7]

Core Insights - Sharecare has partnered with CLEAR to enhance its AskMD platform, which is an AI-enabled health navigation and decision support solution aimed at improving care quality and reducing costs across the healthcare ecosystem [1][2][3] Company Overview - Sharecare is a digital healthcare company that provides software and tech-enabled services to improve care quality, drive better outcomes, and lower costs through data-driven AI insights and comprehensive platforms [8] - CLEAR is a secure identity company that focuses on strengthening security and creating frictionless experiences for its members, with over 36 million members globally [6][7] Partnership Details - The integration of CLEAR's secure identity platform will allow Sharecare to offer a more secure way for users to verify their identity and access AskMD's capabilities, including real-time eligibility and secure data retrieval [2][3] - The partnership aims to support a patient-centered health ecosystem, enabling stakeholders like employers and health systems to improve quality and reduce costs [2][4] Market Impact - The AskMD platform is expected to roll out in 2026 to over 75 million registered consumers and 10 million members from employer and health plan clients, targeting millions of Americans seeking trustworthy medical guidance [3][5] - The collaboration aligns with CMS's Health Tech Ecosystem initiative, which aims to create a connected digital experience for patients and improve community engagement in healthcare [3][4] Future Plans - Sharecare plans to demonstrate measurable outcomes in Georgia, leveraging its Community Well-Being Index, and aims to scale this model nationwide [5]